AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
PTC Therapeutics reported Q3 earnings of $15.9 million, surpassing the average estimate of $1.19 loss per share. Revenue was $211 million, exceeding the expected $175.6 million. The biopharmaceutical company expects full-year revenue between $750 million and $800 million.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet